Phaseline

Companies › Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LY5830966
Type II JAK2 inhibitor
JAK2Phase 1Primary MyelofibrosisJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06343805LY5830966Phase 1Primary MyelofibrosisOncologyJun 2027

Targets

JAK2 (1)

Companies with the same targets

AbbVie Chia Tai Tianqing Pharmaceutical Group Sun Pharmaceutical Industries Alfasigma Bristol-Myers Squibb Takeda Incyte Chengdu Zenitar Biomedical Technology Eli Lilly LEO Pharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.